Eli Lilly & Co. (LLY)

Name: Eli Lilly & Co. (LLY): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Eli Lilly & Co. (LLY) reported revenue of $23.0 billion for Q2 FY2026, the quarter ended 30 June 2026, up 47.7% on the same quarter a year earlier. Net income was $7.1 billion, up 25.3% on the year, and diluted earnings per share $7.94. The figures are the company's own, from the 10-Q it filed with the SEC on 5 August 2026.

Revenue$23.0 billionup 47.7%

Net income$7.1 billionup 25.3%

Diluted EPS$7.94

QuarterQ2 FY2026ended 30 June 2026

Ratios

From the filings

ROE78.8%

ROCEn/a

Operating marginn/a

Net margin33.5%

FCF margin22.8%

Interest covern/a

Debt to equity1.41

Cash conversion1.05

Share count, 1 year-0.5%

Sales CAGR, 3 years31.7%

Profit CAGR, 3 years49.0%

EPS, TTM$29.80

At the close of 21 September 2026

Price$1,164.89

Market cap$1.10 trillion

Stock P/E39.09

Price to book32.37

EV / EBITDAn/a

Dividend yield0.5%

Market cap / sales13.76

52-week high$1,280.34

52-week low$714.59

Price, 1 year54.9%

Price CAGR, 3 years28.4%

Price CAGR, 5 years38.5%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Eli Lilly & Co. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on LLY

Filings	17 in twelve months: 7 current reports (8-K), about 4 results of operations; 1 other events; 1 shareholder vote; 1 officer or director change
Planned insider sales	22 Form 144 notices in twelve months, $5.29 billion; latest 17 August 2026
Options tape	put/call 1.25 by open interest on 23 September 2026; the straddle prices a 2.5% move to 25 September 2026
Holders	16 of the followed funds hold it; largest FMR LLC; 7 Schedule 13D or 13G filings in twelve months
Insider trading	6 sales and 0 purchases on Form 4 in twelve months
Congress	9 House trades disclosed in six months
Short interest	7.9 million shares short, 2.99 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	9,499	9,353	8,768	11,303	11,439	13,533	12,728	15,558	17,601	19,292	19,799	22,974
Cost of revenue	1,860	1,788	1,674	2,170	2,171	2,404	2,224	2,448	3,008	3,372	3,577	3,268
Gross profit	7,638	7,565	7,094	9,133	9,268	11,129	10,504	13,110	14,592	15,920	16,222	19,706
Gross margin	80%	81%	81%	81%	81%	82%	83%	84%	83%	83%	82%	86%
R&D	2,409	2,563	2,523	2,711	2,734	3,022	2,734	3,336	3,466	3,802	3,510	3,819
SG&A	1,804	1,925	1,952	2,117	2,100	2,424	2,469	2,753	2,741	3,132	2,934	3,430
Interest expense	125	138	180	184	193	225	244	249	180	223	n/a	n/a
Pre-tax income	427	2,509	2,536	3,517	1,588	5,039	3,456	6,776	7,232	8,266	8,850	9,247
Tax rate	113%	13%	12%	16%	39%	12%	20%	16%	23%	20%	16%	23%
Net income	-57.4	2,190	2,243	2,967	970	4,410	2,759	5,660	5,582	6,638	7,396	7,095
Net margin	-1%	23%	26%	26%	8%	33%	22%	36%	32%	34%	37%	31%
Diluted EPS	-$0.06	$2.42	$2.48	$3.28	$1.07	$4.88	$3.06	$6.29	$6.21	$7.39	$8.26	$7.94
Operating cash flow	2,190	-312	1,166	1,466	3,712	2,474	1,666	3,087	8,836	3,225	5,333	10,690
Capital expenditure	970	1,071	986	1,225	1,351	1,496	1,510	1,697	2,088	2,547	2,326	2,933
Free cash flow	1,219	-1,382	180	241	2,361	978	156	1,390	6,748	678	3,007	7,757
Buybacks	0.0	0.0	0.0	0.0	446	2,054	1,200	692	708	1,508	2,356	1,601
Dividends paid	1,016	1,018	1,169	1,172	1,170	1,168	1,346	1,347	1,345	1,346	1,548	1,546
Shares outstanding	949m	950m	950m	950m	949m	948m	948m	946m	945m	943m	942m	941m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2014 †	FY2015 †	FY2016 †	FY2017 †	FY2018 †	FY2019	FY2020 †	FY2021 †	FY2022 †	FY2023	FY2024 †	FY2025	TTM
Revenue	19,616	19,959	21,222	19,974	21,493	22,320	24,540	28,318	28,541	34,124	45,043	65,179	79,666
Cost of revenue	4,932	5,037	5,710	4,448	4,682	4,721	5,483	7,313	6,630	7,082	8,418	11,052	13,225
Gross profit	14,683	14,922	15,512	16,720	18,126	17,598	19,056	21,006	21,912	27,042	36,624	54,127	66,441
Gross margin	74.9%	74.8%	73.1%	83.7%	84.3%	78.8%	77.7%	74.2%	76.8%	79.2%	81.3%	83.0%	83.4%
Research and development	4,734	4,796	5,310	5,096	5,051	5,595	5,976	6,931	7,191	9,313	10,991	13,337	14,596
Selling, general and administrative	6,621	6,533	6,528	5,982	5,975	6,214	6,121	6,432	6,440	7,403	8,594	11,094	12,236
Interest expense	149	161	185	225	242	401	360	340	332	486	781	895	n/a
Pre-tax income	3,000	2,790	3,374	2,305	3,680	5,266	7,230	6,156	6,806	6,555	12,680	25,731	33,596
Income tax	610	382	636	2,391	530	628	1,036	574	562	1,314	2,090	5,091	6,884
Effective tax rate	20.3%	13.7%	18.9%	103.7%	14.4%	11.9%	14.3%	9.3%	8.3%	20.1%	16.5%	19.8%	20.5%
Net income	2,390	2,408	2,738	-204	3,232	8,318	6,194	5,582	6,245	5,240	10,590	20,640	26,711
Net margin	12.2%	12.1%	12.9%	-1.0%	15.0%	37.3%	25.2%	19.7%	21.9%	15.4%	23.5%	31.7%	33.5%
Diluted EPS	$2.23	$2.26	$2.58	-$0.19	$3.13	$8.89	$6.79	$6.12	$6.90	$5.80	$11.71	$22.95	$29.80
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2014 †	FY2015 †	FY2016 †	FY2017 †	FY2018 †	FY2019	FY2020 †	FY2021 †	FY2022 †	FY2023	FY2024 †	FY2025	TTM
Operating cash flow	4,458	2,965	4,851	5,616	5,524	4,837	6,500	7,366	7,586	4,240	8,818	16,813	28,084
Capital expenditure	1,163	1,066	1,037	1,077	1,211	1,034	1,388	1,310	1,854	3,448	5,058	7,841	9,893
Free cash flow	3,296	1,898	3,814	4,539	4,314	3,803	5,112	6,056	5,731	792	3,760	8,972	18,190
Free cash flow margin	16.8%	9.5%	18.0%	22.7%	20.1%	17.0%	20.8%	21.4%	20.1%	2.3%	8.3%	13.8%	22.8%
Depreciation and amortisation	1,379	1,428	1,497	1,567	1,609	1,233	1,324	1,548	1,522	1,527	1,767	1,997	2,099
Share-based compensation	156	218	255	281	280	312	308	343	371	628	646	626	649
Buybacks	800	750	600	300	4,151	4,400	500	1,250	1,500	750	2,500	4,108	6,173
Dividends paid	2,101	2,127	2,158	2,192	2,312	2,410	2,687	3,087	3,536	4,069	4,680	5,384	5,785
Dividend per share	n/a	n/a	$2.05	$2.12	$2.33	$2.68	$3.07	$3.53	$4.07	$4.69	$5.40	$6.23	n/a
Diluted shares, weighted	1,074m	1,066m	1,062m	1,052m	1,034m	936m	913m	912m	905m	903m	904m	899m	894m
Shares outstanding at period end	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	941m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2014 †	FY2015 †	FY2016 †	FY2017 †	FY2018 †	FY2019	FY2020 †	FY2021 †	FY2022 †	FY2023	FY2024 †	FY2025	TTM
Total assets	36,308	35,569	38,806	44,981	43,908	39,286	46,633	48,806	49,490	64,006	78,715	112,476	142,283
Cash and equivalents	3,872	3,666	4,582	6,536	7,321	2,338	3,657	3,818	2,067	2,819	3,268	7,268	8,950
Receivables	3,235	3,513	4,029	4,546	4,594	4,547	5,875	6,673	6,896	9,090	11,006	17,760	20,083
Inventory	2,740	3,446	3,562	4,458	3,098	3,191	3,980	3,886	4,310	5,773	7,589	13,744	16,793
Goodwill	1,758	4,040	3,973	4,370	1,367	3,679	3,766	3,892	4,073	4,940	5,770	5,898	8,849
Total debt, as filed	8,022	7,978	10,305	13,647	10,299	15,317	16,595	16,885	16,239	25,225	33,644	42,503	n/a
Long-term debt	5,333	7,978	9,006	9,940	9,196	13,638	16,349	16,741	14,815	19,105	29,474	40,868	47,858
Borrowings, as the company tags them	4,873	7,700	8,776	10,757	9,641	13,638	16,349	16,741	14,815	19,105	29,474	n/a	n/a
Operating lease liabilities	n/a	n/a	n/a	n/a	0.0	487	n/a	n/a	n/a	948	971	1,140	n/a
Shareholders' equity	15,373	14,571	14,008	11,592	9,829	2,607	5,642	8,979	10,650	10,772	14,272	26,535	33,879
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	12.6%	21.6%	31.7%	49.6%
Profit growth, compounded	24.0%	27.2%	49.0%	93.6%
Return on equity, average	80.1%	64.3%	66.9%	77.8%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Pharmaceutical Preparations

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Eli Lilly & Co. LLY	$1.10 trillion	39.09	78.8%	n/a	49.6%	1.41	0.5%
Johnson & Johnson JNJ	$649.4 billion	31.30	24.8%	n/a	8.1%	0.44	1.9%
ABBVIE Inc. ABBV	$467.4 billion	74.71	n/a	26.2%	10.4%	n/a	2.6%
Merck & Co., Inc. MRK	$368.8 billion	119.60	7.6%	n/a	4.6%	1.29	2.2%
Abbott Laboratories ABT	$179.4 billion	28.85	12.1%	17.1%	6.6%	0.57	2.3%
Pfizer Inc. PFE	$158.1 billion	36.50	5.1%	n/a	-0.2%	0.71	6.2%
Vertex Pharmaceuticals Inc. / MA VRTX	$129.4 billion	29.74	21.8%	38.0%	10.2%	0.00	n/a
Bristol-Myers Squibb Co. BMY	$127.9 billion	13.76	41.6%	24.2%	3.1%	1.92	4.0%
Regeneron Pharmaceuticals, Inc. REGN	$84.6 billion	19.77	13.7%	24.7%	9.3%	0.06	0.5%
Zoetis Inc. ZTS	$29.5 billion	11.75	83.1%	n/a	1.4%	2.87	2.8%
Viatris Inc. VTRS	$19.6 billion	n/a	-2.9%	-0.6%	4.4%	0.81	2.8%

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	30 June 2026	5 August 2026	EDGAR
10-Q	31 March 2026	30 April 2026	EDGAR
10-K	31 December 2025	12 February 2026	EDGAR
10-Q	30 September 2025	30 October 2025	EDGAR
10-Q	30 June 2025	7 August 2025	EDGAR
10-Q	31 March 2025	1 May 2025	EDGAR
10-K	31 December 2024	19 February 2025	EDGAR
10-Q	30 September 2024	30 October 2024	EDGAR
10-Q	30 June 2024	8 August 2024	EDGAR
10-Q	31 March 2024	30 April 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install